Customer experience: shaping digital healthcare
|16th September 2019
For many years the industry has promised to democratise healthcare through the invention of digital tools, which enable holistic care.
These services are designed to improve the customer experience. When designed well, they use data and analytics to facilitate better decision-making in the clinic and uncover deeper insights that can result in R&D breakthroughs. However, several barriers are preventing the potential of these tools from being realised.
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance treatment and improve patient and stakeholder outcomes.
Download the magazine to learn:
- Why aren’t doctor’s using digital therapeutics?
- Digital therapeutics and their impact on society
- Designing a global digital patient services platform
- How we should be rethinking electronic medical records
- Digital nation: how Australia became digital health pioneers
- The intelligent pill replacing insulin injections
- How to enhance the lifecycle of your insight
If you would like to find out more about how we can help your brand to reach and engage with your customers in innovative ways, please get in touch with simon.young@bluelatitude.com
Delivering impactful customer engagements in COVID-19
|14th July 2020
Blue Latitude Health, and our parent company Fishawack Health, have developed exclusive intellectual property, processes and tools to ensure you’re engaging customers in the right way. View our service one-pagers below to find out how we can help solve your challenges whether you’re in a medical, brand, portfolio or an above brand role.
Top 5 tips for a multi-indication product launch
|8th July 2020
Senior Associate Consultant Sana Rahim and Senior Consultant Victoria Clark explain the lessons the team has learned from launching six different indications of an oncology product in an accelerated timeframe.
If our patients are diverse, why are clinical trials so white?
|22nd June 2020
Despite facing worse health outcomes, minority populations are often left out of clinical trials and miss the opportunity to participate in life-saving research. Associate Consultant Ling Song explores this issue and calls for the pharmaceutical industry to change its approach.